Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials-Reference-Cited by-同舟云学术

Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials

Published:2023-11-10 Issue:32 Volume:41 Page:5025-5034
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Raetz Elizabeth A.¹^ORCID,Rebora Paola²^ORCID,Conter Valentino³^ORCID,Schrappe Martin⁴^ORCID,Devidas Meenakshi⁵,Escherich Gabriele⁶,Imai Chihaya⁷^ORCID,De Moerloose Barbara⁸^ORCID,Schmiegelow Kjeld⁹¹⁰^ORCID,Burns Melissa A.¹¹,Elitzur Sarah¹²^ORCID,Pieters Rob¹³^ORCID,Attarbaschi Andishe¹⁴¹⁵^ORCID,Yeoh Allen¹⁶^ORCID,Pui Ching-Hon¹⁷^ORCID,Stary Jan¹⁸^ORCID,Cario Gunnar⁴,Bodmer Nicole¹⁹,Moorman Anthony V.²⁰^ORCID,Buldini Barbara²¹^ORCID,Vora Ajay²²^ORCID,Valsecchi Maria Grazia²²³^ORCID

Affiliation:

1. Department of Pediatrics and Perlmutter Cancer Center, NYU Langone Health, New York, NY

2. Bicocca Bioinformatics Biostatistics and Bioimaging Center B4, School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy

3. Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

4. Pediatrics I, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

5. Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN

6. Clinic of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

7. Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

8. Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

9. Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

10. Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Denmark

11. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

12. Schneider Children's Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

13. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands

14. Department of Pediatric Hematology and Oncology, St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria

15. St Anna Children's Cancer Research Institute, Vienna, Austria

16. Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

17. Department of Oncology, St Jude Children's Research Hospital, Memphis, TN

18. Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic

19. Pediatric Hematology and Oncology, Kinderspital Zurich, Zurich, Switzerland

20. Leukaemia Research Cytogenetics Group, Newcastle University Centre for Cancer, Clinical and Translational Institute, Newcastle University, Newcastle, United Kingdom

21. Department of Woman and Child Health, University of Padua, Padua, Italy

22. Department of Haematology, Great Ormond Street Hospital, London, United Kingdom

23. Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

Abstract

Outcome improvement for T-cell acute lymphoblastic leukemia and Induction failure in a contemporary treatment era.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00088

Reference36 articles.

1. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia

2. Incidence and Prognostic Significance of Immunophenotypic Subgroups in Childhood Acute Lymphoblastic Leukemia: Experience of the BFM Study 86

3. Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience

4. Treatment of Acute Lymphoblastic Leukemia

5. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95